INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2023. The put-call ratio across all filers is 2.22 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,878,374 | -7.4% | 4,494,851 | +22.8% | 7.53% | +12.0% |
| Q2 2023 | $20,394,655 | +10.8% | 3,661,518 | +13.9% | 6.72% | -11.3% |
| Q1 2023 | $18,413,848 | +559.0% | 3,213,586 | +20.8% | 7.58% | +524.0% |
| Q4 2022 | $2,794,212 | -60.8% | 2,661,154 | 0.0% | 1.22% | -53.4% |
| Q3 2022 | $7,132,000 | -43.8% | 2,661,154 | 0.0% | 2.61% | -59.2% |
| Q2 2022 | $12,694,000 | +95.1% | 2,661,154 | +67.2% | 6.40% | +107.7% |
| Q1 2022 | $6,508,000 | -40.0% | 1,591,154 | 0.0% | 3.08% | -32.2% |
| Q4 2021 | $10,852,000 | -41.2% | 1,591,154 | 0.0% | 4.54% | -30.4% |
| Q3 2021 | $18,441,000 | -32.0% | 1,591,154 | 0.0% | 6.52% | -39.0% |
| Q2 2021 | $27,113,000 | -13.9% | 1,591,154 | 0.0% | 10.69% | +5.7% |
| Q1 2021 | $31,505,000 | -4.1% | 1,591,154 | 0.0% | 10.11% | -6.6% |
| Q4 2020 | $32,841,000 | – | 1,591,154 | – | 10.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |